T1	p 16 46	epithelial ovarian carcinoma :
T2	p 233 360	patients with epithelial ovarian carcinoma that recurred after or did n't respond to first-line , platinum-based chemotherapy .
T3	p 382 429	Patients with measurable and assessable disease
T4	p 721 756	474 patients were treated ( 239 PLD
T5	i 79 129	pegylated liposomal doxorubicin versus topotecan .
T6	i 176 229	pegylated liposomal doxorubicin ( PLD ) and topotecan
T7	i 464 470	PLD 50
T8	i 520 533	topotecan 1.5
T9	o 153 172	efficacy and safety
T10	o 831 870	overall progression-free survival rates
T11	o 923 967	overall response rates for PLD and topotecan
T12	o 1020 1049	Median overall survival times
T13	o 1210 1235	progression-free survival
T14	o 1317 1339	overall survival , PLD
T15	o 1518 1526	survival
T16	o 1569 1596	Severe hematologic toxicity
T17	o 1670 1739	dosage modification , or growth factor or blood product utilization .
T18	o 1777 1801	favorable safety profile